RISK OF PHARMACOKINETIC DRUG-DRUG INTERACTIONS WITH NOVEL DRUGS APPROVED BY THE US FDA IN 2022: A DETAILED REVIEW OF DDI DATA FROM NDA DOCUMENTATION

被引：0

作者：

Yu, Jingjing ^{[1
]}

Wang, Yan ^{[1
]}

Ragueneau-Majlessi, Isabelle ^{[1
]}

机构：

[1] Certara, Princeton, NJ USA

来源：

DRUG METABOLISM AND PHARMACOKINETICS | 2024年 / 55卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

P69

引用

页数：2

共 34 条

[1] Pharmacokinetic drug-drug interactions: an insight into recent US FDA-approved drugs for prostate cancer
Gajula, Siva Nageswara Rao
Reddy, Gangireddy Navitha
Reddy, Dannarm Srinivas
Sonti, Rajesh
BIOANALYSIS, 2020, 12 (22) : 1647 - 1664
[2] UNDERSTANDING THE RISK OF CLINICALLY SIGNIFICANT PHARMACOKINETIC-BASED DRUG-DRUG INTERACTIONS WITH DRUGS NEWLY APPROVED BY THE US FDA - A REVIEW OF RECENT NEW DRUG APPLICATIONS (2013-2016)
Yu, Jingjing
Ragueneau-Majlessi, Isabelle
DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : S46 - S47
[3] What can be learned from the nda and bla reviews of newly approved drugs? A systematic review of drug interaction data for drugs approved by the US FDA IN 2014
Yu, Jingjing
Ritchie, Tasha K.
Zhou, Zhu
Ragueneau-Majlessi, Isabelle
DRUG METABOLISM REVIEWS, 2016, 48 : 81 - 81
[4] Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications
Yu, Jingjing
Wang, Yan
Ragueneau-Majlessi, Isabelle
CLINICAL THERAPEUTICS, 2022, 44 (11) : 1536 - 1544
[5] Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical RecommendationsS
Yu, Jingjing
Wang, Yan
Ragueneau-Majlessi, Isabelle
DRUG METABOLISM AND DISPOSITION, 2022, 50 (01) : 1 - 7
[6] Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration Between 2013 and 2016
Yu, Jingjing
Zhou, Zhu
Tay-Sontheimer, Jessica
Levy, Rene H.
Ragueneau-Majlessi, Isabelle
DRUG METABOLISM AND DISPOSITION, 2018, 46 (06) : 835 - 845
[7] Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2017
Yu, Jingjing
Petrie, Ichiko D.
Levy, Rene H.
Ragueneau-Majlessi, Isabelle
DRUG METABOLISM AND DISPOSITION, 2019, 47 (02) : 135 - 144
[8] DETECTION OF DRUG-DRUG INTERACTIONS FROM POPULATION PHARMACOKINETIC DATA
GRASELA, TH
ANTAL, EJ
SMITH, RB
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (02) : 196 - 196
[9] Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer
Pilon, Dominic
Ellis, Lorie A.
Xiao, Yongling
Behl, Ajay S.
Lefebvre, Patrick
AMERICAN JOURNAL OF THERAPEUTICS, 2019, 26 (03) : E422 - E424
[10] MAIN MECHANISMS OF PHARMACOKINETIC DRUG-DRUG INTERACTIONS TRIGGERING LABEL RECOMMENDATIONS FOR DRUGS APPROVED BY THE FOOD AND DRUG ADMINISTRATION IN 2018
Yu, Jingjing
Petrie, Ichiko
Ragueneau-Majlessi, Isabelle
DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S49 - S49

← 1 2 3 4 →